Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep;129(3):269-270.
doi: 10.1016/j.anai.2022.06.025.

Where to place etanercept and combination treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis?

Eric M Mukherjee  1 , Elizabeth J Phillips  2
Affiliations
Editorial

Where to place etanercept and combination treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis?

Eric M Mukherjee et al. Ann Allergy Asthma Immunol. 2022 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: EJP receives Royalties from Uptodate and consulting fees from Janssen, Vertex, Biocryst, Regeneron, Verve and AstraZeneca. She is co-director of IIID Pty Ltd that holds a patent for HLA-B*57:01 testing for abacavir hypersensitivity, and has a patent pending for Detection of Human Leukocyte Antigen-A*32:01 in connection with Diagnosing Drug Reaction with Eosinophilia and Systemic Symptoms without any financial remuneration and not directly related to the submitted work.

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, et al. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. J Invest Dermatol 2017; 137:1065–73. - PubMed
    1. Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14:1343–50. - PubMed
    1. Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, et al. Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest 2018; 128:985–96. - PMC - PubMed
    1. Phillips EJ, Bouchard CS, Divito SJ. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Coordinating Research Priorities to Move the Field Forward. JAMA Dermatol 2022. - PMC - PubMed
    1. Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, et al. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol 2017; 153:514–22. - PMC - PubMed

MeSH terms